HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer

(2012) T. Shimamura et al.   CLINICAL CANCER RESEARCH

Management of Small Cell Lung Cancer

(2012) Raffaele Califano et al.   DRUGS

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

(2012) David A. Proia et al.   INVESTIGATIONAL NEW DRUGS

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

(2012) Charles M Rudin et al.   NATURE GENETICS

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

(2012) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration

(2011) Ganta Chaitanya et al.   Cell Communication and Signaling

Second-line therapy for small-cell lung cancer

(2011) Alexander Schmittel   Expert Review of Anticancer Therapy

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

Functional complementation between FADD and RIP1 in embryos and lymphocytes

(2011) Haibing Zhang et al.   NATURE

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

(2011) David A. Proia et al.   PLoS One

Role of Cyclin B1/Cdc2 Up-Regulation in the Development of Mitotic Prometaphase Arrest in Human Breast Cancer Cells Treated with Nocodazole

(2011) Hye Joung Choi et al.   PLoS One

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias

(2010) H. Bansal et al.   BLOOD

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

(2010) David S. Ettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

RIP Kinases at the Crossroads of Cell Death and Survival

(2009) Wim Declercq et al.   CELL

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Retracted:Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis

(2009) Charitha Gangadharan et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation

(2008) Eugene Varfolomeev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Both cIAP1 and cIAP2 regulate TNF -mediated NF- B activation

(2008) D. J. Mahoney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA